si:ch211-238a12.2 Antibody

What is si:ch211-238a12.2 and why is it studied in zebrafish models?

Si:ch211-238a12.2 is a protein-coding gene in zebrafish (Danio rerio) with a molecular weight of approximately 14,686 Da. It has received attention in developmental biology research because it represents a novel target for understanding protein function in vertebrate models. The protein is sometimes referred to as "Protein C19orf12 homolog" and has been identified through genomic analysis of zebrafish .

Research interest in this protein stems from:

• Its potential homology with human proteins

• Its role in zebrafish development

• The accessibility of zebrafish as a model organism for studying vertebrate biology

Methodologically, researchers study this protein through antibody-based detection techniques to understand its expression patterns, localization, and functional roles in normal development and disease models.

What types of si:ch211-238a12.2 antibodies are available for research?

Currently, researchers have access to several antibody formats targeting si:ch211-238a12.2:

The most documented antibody is the rabbit polyclonal against recombinant Danio rerio si:ch211-238a12.2 protein, which has been tested in Western blot and ELISA applications . When selecting an antibody, researchers should consider the specific experimental needs, including the assay type, tissue preparation method, and required sensitivity.

How should researchers validate si:ch211-238a12.2 antibody specificity before experimental use?

Antibody validation is critical for ensuring reproducible results. For si:ch211-238a12.2 antibody, a comprehensive validation protocol should include:

• Western blot validation:

  • Use zebrafish tissue lysates with expected expression

  • Include both positive and negative control tissues

  • Verify correct molecular weight (approximately 14.7 kDa)

  • Perform peptide competition assays to confirm specificity

• Knockout/knockdown controls:

  • Use CRISPR/Cas9 or morpholino knockdown samples

  • Confirm reduced or absent signal in these samples

• Cross-reactivity testing:

  • Test antibody against closely related zebrafish proteins

  • Particularly important for polyclonal antibodies that may recognize conserved epitopes

• Reproducibility assessment:

  • Test multiple antibody lots if available

  • Document batch variations

This rigorous validation approach aligns with the reproducibility guidelines outlined in recent literature on antibody characterization in biomedical research .

What are the optimal protocols for using si:ch211-238a12.2 antibody in Western blot applications?

Based on technical documentation and research protocols, the following methodology is recommended for Western blot applications using si:ch211-238a12.2 antibody:

Sample preparation:

• Homogenize zebrafish tissue in RIPA buffer with protease inhibitors

• Centrifuge at 14,000×g for 15 minutes at 4°C

• Quantify protein concentration using Bradford or BCA assay

Western blot protocol:

• Load 20-30 μg of total protein per lane on 12-15% SDS-PAGE gel (optimal for low molecular weight proteins)

• Transfer to PVDF membrane (recommended over nitrocellulose for this application)

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary antibody (dilution 1:1000 to 1:5000, depending on specific antibody) overnight at 4°C

• Wash 3× with TBST

• Incubate with appropriate secondary antibody (typically anti-rabbit or anti-mouse HRP conjugate at 1:5000) for 1 hour

• Develop using chemiluminescence detection

Troubleshooting tips:

• If background is high, increase blocking time or try alternative blocking agents (BSA instead of milk)

• For weak signals, extend primary antibody incubation or try enhanced detection systems

• Small volumes of antibody may become entrapped in the seal; briefly centrifuge vials before opening

How can researchers assess potential cross-reactivity of si:ch211-238a12.2 antibody with human proteins?

Cross-reactivity assessment is particularly important for translational research. Researchers should:

• Conduct sequence homology analysis:

  • Perform BLAST alignment between zebrafish si:ch211-238a12.2 and human proteome

  • Identify human homologs with highest sequence similarity

  • Focus on epitope regions if known

• Experimental cross-reactivity testing:

  • Test antibody against human cell lysates with expression of potential homologs

  • Include appropriate positive (zebrafish) and negative controls

  • Use immunoprecipitation followed by mass spectrometry to identify any cross-reactive proteins

• Validation in heterologous expression systems:

  • Express human homologs in cell lines lacking endogenous expression

  • Test antibody reactivity against these recombinant proteins

  • Quantify relative binding affinities if positive

• Epitope mapping considerations:

  • If the antibody is generated against a specific peptide, analyze conservation of this epitope

  • Consider using epitope competition assays to confirm specificity

This approach draws on methodologies used in therapeutic antibody development, where cross-reactivity assessment is critical for predicting potential off-target effects .

What are common challenges when using si:ch211-238a12.2 antibody and how can they be addressed?

Researchers frequently encounter these challenges when working with si:ch211-238a12.2 antibody:

Additionally, for frozen antibody aliquots, researchers should avoid repeated freeze-thaw cycles and ensure proper storage at -20°C or -80°C as recommended in the product documentation .

How should researchers interpret unexpected or contradictory results when using si:ch211-238a12.2 antibody?

When faced with unexpected or contradictory results:

• Verify antibody performance:

  • Repeat validation experiments with positive and negative controls

  • Test a different lot or source of antibody if available

  • Consider using alternative detection methods (e.g., mass spectrometry) for confirmation

• Evaluate experimental conditions:

  • Check for inconsistencies in sample preparation or experimental protocols

  • Consider potential post-translational modifications or protein isoforms

  • Review literature for similar unexpected findings with this or related proteins

• Biological interpretation considerations:

  • Consider developmental stage-specific expression patterns

  • Evaluate tissue-specific regulation or protein localization

  • Assess potential protein-protein interactions that might affect epitope accessibility

• Complementary approaches:

  • Corroborate protein expression data with mRNA analysis

  • Use genetic approaches (CRISPR/Cas9) to validate observed phenotypes

  • Consider alternative antibodies targeting different epitopes of the same protein

Researchers should document all validation steps carefully to enhance reproducibility in accordance with recommended practices for antibody characterization in biomedical research .

How can cutting-edge proteomics approaches enhance research using si:ch211-238a12.2 antibody?

Integrating si:ch211-238a12.2 antibody research with advanced proteomics can significantly elevate experimental outcomes:

• Immunoprecipitation-Mass Spectrometry (IP-MS):

  • Use si:ch211-238a12.2 antibody for immunoprecipitation

  • Analyze pulled-down complexes with LC-MS/MS

  • Identify interaction partners and post-translational modifications

  • This approach can uncover previously unknown functions through protein-protein interaction networks

• Proximity-dependent biotin labeling:

  • Generate fusion proteins linking si:ch211-238a12.2 to BioID or APEX2

  • Express in zebrafish using tissue-specific promoters

  • Use the antibody to confirm expression patterns

  • Identify proximal proteins to map cellular microenvironments

• Single-cell proteomics integration:

  • Combine antibody-based detection with single-cell isolation techniques

  • Analyze protein expression heterogeneity across tissues

  • Correlate with single-cell transcriptomics data

• Structural epitope mapping:

  • Use hydrogen-deuterium exchange mass spectrometry to map epitope regions

  • Identify critical binding residues

  • Improve antibody design for future iterations

These approaches align with recent developments in antibody-based therapeutics research and can significantly advance understanding of si:ch211-238a12.2 function .

What considerations should researchers keep in mind when designing experiments to study si:ch211-238a12.2 function in disease models?

When employing si:ch211-238a12.2 antibody in disease model research:

• Model selection and validation:

  • Choose appropriate zebrafish disease models relevant to the suspected function

  • Verify si:ch211-238a12.2 expression in the model using the antibody

  • Consider genetic models (CRISPR/Cas9) alongside chemical or environmental perturbations

• Temporal dynamics assessment:

  • Design time-course experiments to capture dynamic changes

  • Use the antibody for both Western blot and immunohistochemistry at multiple timepoints

  • Correlate protein changes with disease progression markers

• Therapeutic intervention evaluation:

  • Use the antibody to monitor protein levels during treatment

  • Assess whether intervention normalizes expression patterns

  • Consider developing neutralizing antibodies if the protein has extracellular domains

• Translational potential assessment:

  • If human homologs exist, parallel experiments with human samples

  • Evaluate conservation of functional pathways between species

  • Test cross-reactivity with human proteins when appropriate

• Controls and reproducibility:

  • Include appropriate genetic controls (e.g., siblings, rescue experiments)

  • Document antibody validation specifically in the disease model context

  • Consider biological replicates across different genetic backgrounds

These approaches build upon methodologies used in antibody characterization for therapeutic development and address the critical need for reproducibility in antibody-based research .